{"DataElement":{"publicId":"6712215","version":"1","preferredName":"Population Pharmacokinetic Study Coagulation Factor VIII Extend Half Life One-Stage Clotting Factor Assay","preferredDefinition":"A study of the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body._Coagulation factor VIII (2351 aa, ~267 kDa) is encoded by the human F8 gene. This protein plays a role in the modulation of coagulation factor IX activity and blood coagulation._To increase in length or duration._The amount of time needed for a material to lose half of its physical, chemical, or biological activity._Any finite or infinite collection of subjects from which a sample is drawn for a study to obtain estimates for values that would be obtained if the entire population were sampled. [AMA style Manual]_A clotting factor assay where FVIII?deficient plasma is added to test plasma and the APTT reagent, mixed and incubated for 3?5 min. The mixture is then recalcified, and the coagulation time is recorded and compared to a standard curve.","longName":"Popu_Phar_FactorVIII_Ext_Half_","context":"PhenX","contextVersion":"1","DataElementConcept":{"publicId":"6712207","version":"1","preferredName":"Population Pharmacokinetic Study Coagulation Factor VIII Extend Half Life","preferredDefinition":"A study of the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body._Coagulation factor VIII (2351 aa, ~267 kDa) is encoded by the human F8 gene. This protein plays a role in the modulation of coagulation factor IX activity and blood coagulation._To increase in length or duration._The amount of time needed for a material to lose half of its physical, chemical, or biological activity._Any finite or infinite collection of subjects from which a sample is drawn for a study to obtain estimates for values that would be obtained if the entire population were sampled. [AMA style Manual]","longName":"Popu_Phar_FactorVIII_Ext_Half","context":"PhenX","contextVersion":"1","ObjectClass":{"publicId":"6706636","version":"1","preferredName":"Population Group Pharmacokinetic Study","preferredDefinition":"A group of individuals united by a common factor (e.g., geographic location, ethnicity, disease, age, gender):A study of the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body.","longName":"C17005:C49663","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Population Group","conceptCode":"C17005","definition":"A group of individuals united by a common factor (e.g., geographic location, ethnicity, disease, age, gender)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pharmacokinetic Study","conceptCode":"C49663","definition":"A study of the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"871581F0-C744-1C0F-E053-F662850AAFE3","latestVersionIndicator":"Yes","beginDate":"2019-04-21","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-21","modifiedBy":"ONEDATA","dateModified":"2019-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6706647","version":"1","preferredName":"Coagulation Factor VIII Extend Half Life","preferredDefinition":"Coagulation factor VIII (2351 aa, ~267 kDa) is encoded by the human F8 gene. This protein plays a role in the modulation of coagulation factor IX activity and blood coagulation.:To increase in length or duration.:The amount of time needed for a material to lose half of its physical, chemical, or biological activity.","longName":"C16571:C25270:C70916","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Coagulation Factor VIII","conceptCode":"C16571","definition":"Coagulation factor VIII (2351 aa, ~267 kDa) is encoded by the human F8 gene. This protein plays a role in the modulation of coagulation factor IX activity and blood coagulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Extend","conceptCode":"C25270","definition":"To increase in length or duration.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Half Life","conceptCode":"C70916","definition":"The amount of time needed for a material to lose half of its physical, chemical, or biological activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"871621AB-70FD-1BF3-E053-F662850AB237","latestVersionIndicator":"Yes","beginDate":"2019-04-21","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-21","modifiedBy":"ONEDATA","dateModified":"2019-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87362511-B234-24FC-E053-F662850A59E3","latestVersionIndicator":"Yes","beginDate":"2019-04-23","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-23","modifiedBy":"PANH","dateModified":"2019-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6732888","version":"1","preferredName":"One-Stage Clotting Factor Assay","preferredDefinition":"A clotting factor assay where FVIII?deficient plasma is added to test plasma and the APTT reagent, mixed and incubated for 3?5 min. The mixture is then recalcified, and the coagulation time is recorded and compared to a standard curve.","longName":"6732888v1.0","context":"PhenX","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6732887","version":"1","preferredName":"One-Stage Clotting Factor Assay","preferredDefinition":"A clotting factor assay where FVIII‐deficient plasma is added to test plasma and the APTT reagent, mixed and incubated for 3–5 min. The mixture is then recalcified, and the coagulation time is recorded and compared to a standard curve.","longName":"C159550","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"One-Stage Clotting Factor Assay","conceptCode":"C159550","definition":"A clotting factor assay where FVIII-deficient plasma is added to test plasma and the APTT reagent, mixed and incubated for 3-5 min. The mixture is then recalcified, and the coagulation time is recorded and compared to a standard curve.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"876F43BC-40A9-5EB3-E053-F662850A4510","latestVersionIndicator":"Yes","beginDate":"2019-04-26","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"876F43BC-40BA-5EB3-E053-F662850A4510","latestVersionIndicator":"Yes","beginDate":"2019-04-26","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-26","modifiedBy":"PANH","dateModified":"2019-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2793652","version":"1","longName":"PhenX","context":"PhenX","ClassificationSchemeItems":[{"publicId":"6641385","version":"1","longName":"Hemophilia","context":"PhenX"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Data Element Population Pharmacokinetic Study Coagulation Factor VIII Extend Half Life One-Stage Clotting Factor Assay does not have Preferred Question Text","type":"Preferred Question Text","description":"Data Element Population Pharmacokinetic Study Coagulation Factor VIII Extend Half Life One-Stage Clotting Factor Assay does not have Preferred Question Text","url":null,"context":"PhenX"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"87361ACC-087F-248B-E053-F662850A7052","latestVersionIndicator":"Yes","beginDate":"2019-04-23","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-23","modifiedBy":"PANH","dateModified":"2020-06-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}